Article
Immunology
Vera Portillo, Stavroula Masouridi-Levrat, Lena Royston, Sabine Yerly, Manuel Schibler, Maria Mappoura, Sarah Morin, Federica Giannotti, Anne-Claire Mamez, Christian van Delden, Yves Chalandon, Dionysios Neofytos
Summary: Positive CMV serology in allogeneic hematopoietic cell transplant recipients (allo-HCTRs) may be false-positive due to transfusion-associated passive immunity. Reclassifying CMV status can help accurately assess the risk of CMV infection in these patients.
CLINICAL INFECTIOUS DISEASES
(2023)
Review
Virology
Carlos Solano, Estela Gimenez, Eliseo Albert, Jose L. Pinana, David Navarro
Summary: Letermovir has been approved by the US FDA for prophylaxis of CMV infection in adult allogeneic stem cell transplant recipients. Real-world experience has validated the clinical trial results, showing that it significantly reduces the risk of CMV infection and improves survival. However, further investigation is needed to address issues such as viral load threshold, impact on CMV-specific T-cell responses, and prevention of LMV-resistant strains.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Pharmacology & Pharmacy
Steven B. Kleiboeker
Summary: Cytomegalovirus (CMV) is a significant human pathogen, with low but impactful prevalence of drug resistance mutations. In this study, 30.04% of patient samples showed resistance to one or more anti-CMV drugs, with most resistance mutations found in UL97. Rapid monitoring for resistance in suspected cases allows for tailored treatment based on objective results instead of empirical drug selection.
ANTIVIRAL RESEARCH
(2023)
Article
Immunology
Alicja Sadowska-Klasa, Wendy M. Leisenring, Ajit P. Limaye, Michael Boeckh
Summary: A systematic review of randomized and observational studies from 2013-2023 indicated that antiviral preemptive therapy initiated at cytomegalovirus viral load thresholds between 2 and 3 log10 IU/mL had comparable cytomegalovirus disease rates. Thus, viral thresholds within this range appeared to effectively safeguard patients who did not receive prophylaxis.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Review
Infectious Diseases
Nipat Chuleerarux, Saman Nematollahi, Achitpol Thongkam, M. Veronica Dioverti, Kasama Manothummetha, Pattama Torvorapanit, Nattapong Langsiri, Navaporn Worasilchai, Rongpong Plongla, Ariya Chindamporn, Anawin Sanguankeo, Nitipong Permpalung
Summary: This study aimed to determine the relationship between CMV infection/serostatus and IFIs in allo-HSCT populations. The results showed that post-transplant CMV infection and high-risk CMV serostatus increased the risk of IFIs, while low-risk CMV serostatus decreased the risk of IFIs.
CLINICAL MICROBIOLOGY AND INFECTION
(2022)
Review
Infectious Diseases
Fareed Khawaja, Amy Spallone, Camille N. Kotton, Roy F. Chemaly
Summary: This article reviews current and emerging CMV antiviral drugs and discusses future perspectives in the field. Despite advancements, there is still a significant need for effective and well-tolerated therapies.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Virology
Guy Shapira, Hadas Volkov, Itai Fabian, David W. Mohr, Maria Bettinotti, Noam Shomron, Robin K. Avery, Ravit Arav-Boger
Summary: This study identified genetic factors associated with protection against CMV infection in transplant recipients. A whole-exome association study was conducted in two cohorts of kidney transplant recipients, and several single-nucleotide polymorphisms (SNPs) were found to be significantly associated with protection from CMV DNAemia. Copy number variation of certain genes was also found to be significantly different between recipients with and without CMV DNAemia. These findings provide new predictive genetic markers for CMV infection protection.
Article
Cardiac & Cardiovascular Systems
Manreet K. Kanwar, Kiran K. Khush, Sean Pinney, Claire Sherman, Shelley Hall, Jeffrey Teuteberg, Nir Uriel, Jon Kobashigawa
Summary: The study found that CMV infection in heart transplant recipients is associated with an increase in AlloMap score, while AlloSure results do not appear to be impacted.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2021)
Article
Oncology
Jennifer M. Geris, Logan G. Spector, Ruth M. Pfeiffer, Ajit P. Limaye, Kelly J. Yu, Eric A. Engels
Summary: The study found that CMV status was not associated with the risk of most cancers among SOT recipients, but the inverse association with DLBCL may reflect the protective effects of CMV prophylaxis or treatment against EBV infection.
Article
Immunology
Aurora Paez-Vega, Belen Gutierrez-Gutierrez, Maria L. Aguera, Carme Facundo, Dolores Redondo-Pachon, Marta Suner, Maria O. Lopez-Oliva, Jose R. Yuste, Miguel Montejo, Cristina Galeano-Alvarez, Juan C. Ruiz-San Millan, Ibai Los-Arcos, Domingo Hernandez, Mario Fernandez-Ruiz, Patricia Munoz, Jorge Valle-Arroyo, Angela Cano, Alberto Rodriguez-Benot, Marta Crespo, Cristian Rodelo-Haad, Maria A. Lobo-Acosta, Jose C. Garrido-Gracia, Elisa Vidal, Luis Guirado, Sara Cantisan, Julian Torre-Cisneros
Summary: For CMV-seropositive kidney transplant recipients receiving ATG induction, it is safe and effective to discontinue prophylaxis when CMV-CMI is recovered, as there is no significant increase in the incidence of CMV replication or disease. Immunoguided prevention is not inferior to prophylaxis in preventing CMV complications.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Nina Singh, Drew J. Winston, Raymund R. Razonable, G. Marshall Lyon, Fernanda P. Silveira, Marilyn M. Wagener, Ajit P. Limaye
Summary: A majority of D+/R- liver transplant recipients experience a significant increase in viral load after preemptive therapy initiation, which is associated with a lower risk of subsequent recurrent viremia.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Sarah Mafi, Marie Essig, Jean-Philippe Rerolle, Gisele Lagathu, Romain Crochette, Veronique Brodard, Betoul Schvartz, Stephanie Gouarin, Nicolas Bouvier, Ilka Engelmann, Antoine Garstka, Celine Bressollette-Bodin, Diego Cantarovitch, Raphaele Germi, Benedicte Janbon, Christine Archimbaut, Anne-Elizabeth Heng, Francoise Garnier, Melissa Gomes-Mayeras, Anais Labrunie, Sebastien Hantz, Sophie Alain
Summary: Cytomegalovirus (CMV) is a common infectious complication following solid organ transplantation. Torque teno viruses (TTV) viremia and QuantiFERON((R))-CMV (QF-CMV) assay markers have shown potential in predicting CMV reactivation in kidney transplant recipients (KTR). The combination of TTV load and QF-Ag or TTV load and QF-Mg may help stratify the risk of CMV reactivation and impact the duration of prophylaxis in these patients.
FRONTIERS IN MEDICINE
(2023)
Article
Surgery
Stephanie Golob, Jaya Batra, Ersilia M. DeFilippis, Matan Uriel, Matt Carey, Maureen Gaine, Angelo Mabasa, Justin Fried, Jayant Raikelkar, Susan Restaino, Sun Hi Lee, Farhana Latif, Melana Yuzefpolskaya, Paolo C. Colombo, Jason Choe, David Majure, Douglas Jennings, Marcus R. Pereira, Kevin Clerkin, Gabriel Sayer, Nir Uriel
Summary: This study evaluated the safety and efficacy of Letermovir as a prophylactic agent for CMV in heart transplant recipients. The results showed that Letermovir is an effective alternative to valganciclovir, but close monitoring for breakthrough CMV and calcineurin inhibitor levels is necessary.
CLINICAL TRANSPLANTATION
(2022)
Review
Microbiology
Nipat Chuleerarux, Achitpol Thongkam, Kasama Manothummetha, Saman Nematollahi, Veronica Dioverti-Prono, Pattama Torvorapanit, Nattapong Langsiri, Navaporn Worasilchai, Rongpong Plongla, Ariya Chindamporn, Anawin Sanguankeo, Nitipong Permpalung
Summary: This study systematically reviewed and meta-analyzed the impact of cytomegalovirus infection on the development of invasive aspergillosis in solid organ transplant recipients. The results showed that post-transplant CMV significantly increased the risk of subsequent IA development. Further research is needed to understand the effectiveness of fungal surveillance or antifungal prophylaxis in preventing this fungal-after-viral phenomenon in transplant recipients.
Article
Multidisciplinary Sciences
Monica Rika Nakamura, Lucio R. Requiao-Moura, Roberto Mayer Gallo, Camila Botelho, Julia Taddeo, Laila Almeida Viana, Claudia Rosso Felipe, Jose Medina-Pestana, Helio Tedesco-Silva
Summary: The study compares the effectiveness of preemptive treatment for cytomegalovirus (CMV) infection after kidney transplant using antigenemia and RT-PCR testing. It finds that both methods yield similar results in preventing CMV disease and related events. Acute rejection and glomerular filtration rate are identified as risk factors for CMV disease.
SCIENTIFIC REPORTS
(2022)